JP2010518088A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518088A5 JP2010518088A5 JP2009549126A JP2009549126A JP2010518088A5 JP 2010518088 A5 JP2010518088 A5 JP 2010518088A5 JP 2009549126 A JP2009549126 A JP 2009549126A JP 2009549126 A JP2009549126 A JP 2009549126A JP 2010518088 A5 JP2010518088 A5 JP 2010518088A5
- Authority
- JP
- Japan
- Prior art keywords
- unit dosage
- picoplatin
- dosage form
- composition
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 claims description 74
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims description 70
- 229950005566 picoplatin Drugs 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 64
- 239000000203 mixture Substances 0.000 claims description 57
- 239000002775 capsule Substances 0.000 claims description 34
- 238000009472 formulation Methods 0.000 claims description 21
- 150000001720 carbohydrates Chemical class 0.000 claims description 18
- 235000014633 carbohydrates Nutrition 0.000 claims description 18
- 235000010980 cellulose Nutrition 0.000 claims description 15
- 229920002678 cellulose Polymers 0.000 claims description 15
- 239000001913 cellulose Substances 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 239000002270 dispersing agent Substances 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 8
- -1 alkaline earth metal salt Chemical class 0.000 claims description 8
- 229920003086 cellulose ether Polymers 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 150000004665 fatty acids Chemical class 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 6
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 229910052697 platinum Inorganic materials 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 239000011859 microparticle Substances 0.000 claims description 5
- 239000003605 opacifier Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 229910010413 TiO 2 Inorganic materials 0.000 claims description 4
- 150000002016 disaccharides Chemical class 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 238000010902 jet-milling Methods 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000037406 food intake Effects 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 229940057948 magnesium stearate Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 claims description 2
- 229910044991 metal oxide Inorganic materials 0.000 claims description 2
- 150000004706 metal oxides Chemical class 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- 229940069328 povidone Drugs 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88920107P | 2007-02-09 | 2007-02-09 | |
| US88967507P | 2007-02-13 | 2007-02-13 | |
| US98415607P | 2007-10-31 | 2007-10-31 | |
| US98902007P | 2007-11-19 | 2007-11-19 | |
| PCT/US2008/001746 WO2008097658A1 (en) | 2007-02-09 | 2008-02-08 | Encapsulated picoplatin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010518088A JP2010518088A (ja) | 2010-05-27 |
| JP2010518088A5 true JP2010518088A5 (https=) | 2012-03-29 |
Family
ID=39682045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009549126A Pending JP2010518088A (ja) | 2007-02-09 | 2008-02-08 | カプセル化されたピコプラチン |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20100062056A1 (https=) |
| EP (1) | EP2109451A4 (https=) |
| JP (1) | JP2010518088A (https=) |
| KR (2) | KR20090109130A (https=) |
| CN (1) | CN101663040A (https=) |
| AU (1) | AU2008214199A1 (https=) |
| BR (1) | BRPI0806362A2 (https=) |
| CA (1) | CA2677639A1 (https=) |
| IL (1) | IL200261A0 (https=) |
| MX (1) | MX2009008487A (https=) |
| RU (1) | RU2009133447A (https=) |
| WO (1) | WO2008097658A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168661B2 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| EP2178893A4 (en) * | 2007-07-16 | 2012-09-19 | Poniard Pharmaceuticals Inc | ORAL FORMULATIONS FOR PICOPLATIN |
| WO2009099649A1 (en) * | 2008-02-08 | 2009-08-13 | Poniard Pharmaceuticals, Inc. | Use of picoplatin and bevacizumab to treat colorectal cancer |
| EP2418955A4 (en) * | 2009-04-15 | 2012-11-21 | Poniard Pharmaceuticals Inc | ORAL PICOPLATIN ANTITUMOR THERAPY WITH HIGH BIOAVAILABILITY |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4419340A (en) * | 1969-03-24 | 1983-12-06 | University Of Delaware | Controlled release of anticancer agents from biodegradable polymers |
| US4302446A (en) * | 1979-10-02 | 1981-11-24 | Bristol-Myers Company | Pharmaceutical compositions |
| MX9203808A (es) * | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
| JP2657393B2 (ja) * | 1988-05-18 | 1997-09-24 | 日本化薬株式会社 | 化学塞栓療法剤 |
| DK0707475T3 (da) * | 1993-06-14 | 1997-12-29 | Janssen Pharmaceutica Nv | Langsom frigørende, filmcoatet tablet af astemizol og pseudoephedrin |
| US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| GB9502799D0 (en) * | 1995-02-14 | 1995-04-05 | Johnson Matthey Plc | Improvements in platinum complexes |
| DE19847618A1 (de) * | 1998-10-15 | 2000-04-20 | Basf Ag | Verfahren zur Herstellung von festen Dosierungsformen |
| US6894049B1 (en) * | 2000-10-04 | 2005-05-17 | Anormed, Inc. | Platinum complexes as antitumor agents |
| SE0004671D0 (sv) * | 2000-12-15 | 2000-12-15 | Amarin Dev Ab | Pharmaceutical formulation |
| JP2005502653A (ja) * | 2001-08-20 | 2005-01-27 | トランセーヴ・インコーポレーテッド | 肺ガンの治療方法 |
| JP2006502233A (ja) * | 2002-08-02 | 2006-01-19 | トランセーブ，インク． | 白金凝集物およびその製造方法 |
| EP1547596A4 (en) * | 2002-09-06 | 2008-11-19 | Western Therapeutics Inst Inc | MEDICAL COMPOSITION AND METHOD FOR THE TREATMENT OF MALIGNANT TUMORS AND THE USE THEREOF |
| DE10325989A1 (de) * | 2003-06-07 | 2005-01-05 | Glatt Gmbh | Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung |
| WO2005077385A2 (en) * | 2004-02-18 | 2005-08-25 | Gpc Biotech Ag | Methods for treating resistant or refractory tumors |
| ES2401992T3 (es) * | 2004-12-30 | 2013-04-26 | Pierre Fabre Medicament | Dispersión sólida estable de un derviado de alcaloide de vinca y procedimiento para su preparación |
| US20090047365A1 (en) * | 2005-02-28 | 2009-02-19 | Eisai R & D Management Co., Ltd. | Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent |
| WO2006104668A2 (en) * | 2005-03-11 | 2006-10-05 | Temple University - Of The Commonwealth System Of Higher Education | Composition and methods for the treatment of proliferative diseases |
| US8143236B2 (en) * | 2005-12-13 | 2012-03-27 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods |
| US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) * | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| US7687487B2 (en) * | 2007-04-19 | 2010-03-30 | Bionumerik Pharmaceuticals, Inc. | Camptothecin-analog with a novel, “flipped” lactone-stable, E-ring and methods for making and using same |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| EP2178893A4 (en) * | 2007-07-16 | 2012-09-19 | Poniard Pharmaceuticals Inc | ORAL FORMULATIONS FOR PICOPLATIN |
| WO2009099649A1 (en) * | 2008-02-08 | 2009-08-13 | Poniard Pharmaceuticals, Inc. | Use of picoplatin and bevacizumab to treat colorectal cancer |
-
2008
- 2008-02-08 JP JP2009549126A patent/JP2010518088A/ja active Pending
- 2008-02-08 MX MX2009008487A patent/MX2009008487A/es not_active Application Discontinuation
- 2008-02-08 CA CA002677639A patent/CA2677639A1/en not_active Abandoned
- 2008-02-08 AU AU2008214199A patent/AU2008214199A1/en not_active Abandoned
- 2008-02-08 EP EP08725387A patent/EP2109451A4/en not_active Withdrawn
- 2008-02-08 BR BRPI0806362-1A patent/BRPI0806362A2/pt not_active IP Right Cessation
- 2008-02-08 CN CN200880011347A patent/CN101663040A/zh active Pending
- 2008-02-08 KR KR1020097018781A patent/KR20090109130A/ko not_active Ceased
- 2008-02-08 WO PCT/US2008/001746 patent/WO2008097658A1/en not_active Ceased
- 2008-02-08 KR KR1020157030498A patent/KR20150125728A/ko not_active Ceased
- 2008-02-08 RU RU2009133447/15A patent/RU2009133447A/ru not_active Application Discontinuation
-
2009
- 2009-08-05 US US12/536,311 patent/US20100062056A1/en not_active Abandoned
- 2009-08-06 IL IL200261A patent/IL200261A0/en unknown
-
2012
- 2012-09-27 US US13/629,108 patent/US20130202690A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010518088A5 (https=) | ||
| RU2009133447A (ru) | Дозированная форма пикоплатина | |
| JP5783489B2 (ja) | トロスピウムの１日１回剤形 | |
| ES2252875T3 (es) | Forma de dosificacion farmaceutica oral de libeeracion prolongada. | |
| US20110008426A1 (en) | Modified release pharmaceutical compositions comprising mycophenolate and processes thereof | |
| US10898439B2 (en) | Methods for treating helicobacter pylori infection | |
| WO2006011159A2 (en) | Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability | |
| HU186078B (en) | Process for producing pharmaceutical compositions for peroral application containing dipyridamol | |
| KR102381586B1 (ko) | 메살라진의 경구용 약제학적 조성물 | |
| CN112618505B (zh) | 一种宠物用含有贝那普利和匹莫苯丹的复方药物组合物及其制备方法 | |
| JP2018118936A (ja) | 腸溶層破損防止用組成物 | |
| JP2010518089A5 (https=) | ||
| US20070122481A1 (en) | Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer | |
| EP1680100A1 (en) | Compositions of quaternary ammonium containing bioavailability enhancers | |
| US20130251793A1 (en) | Pharmaceutical composition comprising phentermine and topiramate | |
| JP4221299B2 (ja) | フィルム錠剤製造用リバビリン顆粒 | |
| WO2022061058A1 (en) | Multiparticulate dosage forms comprising deutetrabenazine | |
| WO2004089333A2 (en) | A stable benzimidazole formulation | |
| US20200061053A1 (en) | Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases | |
| JP2008535920A (ja) | 癌の治療のための、フルオロシチジン誘導体を含む改変放出組成物 | |
| RU123325U1 (ru) | Гранула противотуберкулезного лекарственного средства | |
| KR100505898B1 (ko) | 철분함유 고밀도 펠렛 조성물 및 이의 제조방법 | |
| JP2023138749A (ja) | 腸溶性製剤 | |
| BR122025009427A2 (pt) | Composições de gama-hidroxibutirato, usos de gama-hidroxibutirato e métodos de preparação das composições e micropartículas de liberação modificada ou imediata de oxibato de sódio |